From the Financial Post:
Pfizer Inc said on Monday that U.S. regulators approved its AIDS drug, Selzentry, the first in a new class of oral HIV medicines.
Selzentry is the first drug designed to keep the HIV virus that causes AIDS from entering healthy immune cells. Older AIDS medicines attack the virus itself.
The drug, also known as maraviroc, blocks the CCR5 co-receptor that serves as a main doorway for the HIV virus into immune cells.
The U.S. Food and Drug Administration approved Selzentry for use in patients who have tried other medicines and for those for whom a diagnostic test has confirmed their HIV strain is linked to the CCR5 receptor. About 50 percent to 60 percent of patients who have been treated with other AIDS drugs meet that definition, the FDA said.
Selzentry will come with a "black box" warning, the strongest for prescription drugs, about the risk of liver toxicity, the FDA said. ...more
Links to the latest news in the world of pharmacy with a focus on items most relevant to Canadian pharmacists or others that are interested in Canadian pharmacies. This includes news about Canadian pharmacy seen in the mainstream media on topics such as new drug information and the international pharmacy industry.
Tuesday, August 14, 2007
Pfizer wins U.S. approval for new HIV drug
My understanding is that Selzentry will likely be approved in Canada later this year.
No comments:
Post a Comment